<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640276</url>
  </required_header>
  <id_info>
    <org_study_id>CWP_PTV_706</org_study_id>
    <nct_id>NCT00640276</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome</brief_title>
  <acronym>ProPit</acronym>
  <official_title>A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will identify the influence of long-term treatment of Pitavastatin compared to
      non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic
      syndrome component score. And we will additionally observe the changes of CVD risk factors
      like lipid profile, abdominal fat, insulin resistance and so on.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change of metabolic syndrome risk component</measure>
    <time_frame>48week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin</measure>
    <time_frame>48week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of abdominal visceral fat</measure>
    <time_frame>48week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of insulin resistance : OGTT(75g), HOMA</measure>
    <time_frame>48week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle modification + active drug(Pitavastatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lifestyle Modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <description>Pitavastatin 2mg daily once</description>
    <arm_group_label>T</arm_group_label>
    <other_name>Livaro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Modification</intervention_name>
    <description>conducting mainly exercises and diet</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 75

          -  Patients with LDL ≥ 100mg/dL

          -  Patients with metabolic syndrome

               1. IFG: Fasting glucose ≥ 100mg/dL

               2. Abdominal Obesity: Waist circumference: men≥90cm,women≥85cm

               3. 1 or more of the following

                    1. Triglyceride ≥ 150mg/dL

                    2. HDL-C: men &lt; 40mg/dL, women &lt; 50mg/dL

                    3. Blood pressure: SBP ≥ 130mmHg or DBP ≥ 85mmHg or subject receiving
                       anti-hypertensive treatment

        Exclusion Criteria:

          -  uncontrolled hypertension (DBP ≥ 95mmHg)

          -  taking diabetic drugs or with HbA1c &gt; 8%

          -  LDL ≥ 190mg/dL or Triglyceride ≥ 400mg/dL

          -  coronary heart disease or other diseases caused by artherosclerosis

          -  malignancy within 6 months

          -  Serum creatinine ≥ 2.0mg/dL

          -  ALT or AST ≥ ULN*2.5

          -  CPK ≥ ULN*2

          -  hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Beom Lee</last_name>
    <role>Study Chair</role>
    <affiliation>Hanyang Univ. Guri Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hak Chul Jang</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang-gu</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang Univ. Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pitavastatin</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>metabolic syndrome risk score</keyword>
  <keyword>hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

